Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Buy” by Brokerages

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been assigned an average recommendation of “Buy” from the fifteen ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, twelve have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $48.85.

A number of equities research analysts have recently commented on DYN shares. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Scotiabank started coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. Piper Sandler dropped their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a report on Friday, February 28th. Finally, BMO Capital Markets initiated coverage on Dyne Therapeutics in a report on Wednesday. They issued an “outperform” rating and a $50.00 price objective on the stock.

Dyne Therapeutics Trading Up 1.4 %

Shares of DYN stock opened at $12.05 on Friday. The business’s fifty day simple moving average is $14.83 and its 200-day simple moving average is $25.63. The company has a market cap of $1.36 billion, a PE ratio of -3.38 and a beta of 1.11. Dyne Therapeutics has a 12-month low of $11.18 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities analysts forecast that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the completion of the transaction, the insider now owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold a total of 6,237 shares of company stock valued at $77,760 over the last quarter. 20.77% of the stock is owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors have recently modified their holdings of the business. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics in the third quarter worth $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the third quarter worth $36,000. US Bancorp DE grew its stake in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Dyne Therapeutics during the fourth quarter worth $50,000. Finally, KBC Group NV grew its stake in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.